Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Application Number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Postr Art Unit Examiner Name MEIN Attorney Docket Number		10809185	
		2004-03-25	
		rel	
		3623	
		NECKE DIAZ, SUSANNA M	
		370-029IB	_

		Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	4941090		1990-07-10	McCarthy		
	2	5117355		1992-05-26	McCarthy		
	3	5202826		1993-04-13	McCarthy		
	4	Re36116		1999-02-23	McCarthy		
If you wish to add additional U.S. Patent citation information please click the Add button.						Add	
U.S.PATENT APPLICATION PUBLICATIONS Remove							
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	20030225618	A1	2003-12-04	Hessburg et al.		
2 20010054003 A1 2001-12-20		2001-12-20	Chien et al.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10809185		
Filing Date		2004-03-25		
First Named Inventor	Postrel			
Art Unit		3623		
Examiner Name	MEIN	IECKE DIAZ, SUSANNA M		
Attorney Docket Number		370-029IB		

Date Considered

	3	20030236712	A1	2003-1	2-25	Antonucci et a	ı.		
If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
				FORE	GN PAT	TENT DOCUM	ENTS	Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
	1								
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initials* No look, magazine, journat, serial, symposium, catalog, etc), date, pages(e), volume-issue number(s), publisher, city andior country where published.						Тs			
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
	FXAMINER SIGNATURE								

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10809185
Filing Date		2004-03-25
First Named Inventor	Postr	el
Art Unit		3623
Examiner Name	MEIN	ECKE DIAZ, SUSANNA M
Attorney Docket Numb	er	370-029IB

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

 See attached certification statement

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/arbarkume/	Date (YYYY-MM-DD)	2006-04-25						
Name/Print	Anthony R Barkume	Registration Number	33831						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via stife of manaplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.